Novartis AG ADR Stock

Price

Target price

/ Tradegate WKN: 907122 / Symbol: NVS / Name: Novartis / Stock / Pharmaceuticals / Large Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

JS chart by amCharts

From: to:

Zoom:

Loading data...

Your prediction

Novartis AG ADR Stock

The price for the Novartis AG ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.480%).

With 4 Buy predictions and 3 Sell predictions the community is currently undecided on Novartis AG ADR.

On the other hand, the target price of 103 € is below the current price of 103.5 € for Novartis AG ADR, so the potential is actually -0.48%.

So far the community has only identified positive things for Novartis AG ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

What does Novartis do?

Pros and Cons of Novartis AG ADR in the next few years

Pros

G***** c******* t* c**********

B****

M***** P*******

Cons

S********** s********

W********* I********* f** t** n*** y****

C******** o* t** e**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Novartis AG ADR vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Novartis AG ADR
Roche Holding AG ADR
Bayer AG ADR
Astrazeneca ADR

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-04-15

Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.

Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.

Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.

Feedback